- Title: Subtitle
- 40 - High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies
- Creators
- Boglarka GyurkoczaRajneesh NathStuart E. SeropianHannah ChoeMark R. LitzowNebu KoshyPatrick StiffCamille AbboudBenjamin TomlinsonSunil AbhyankarParameswaran HariGeorge L ChenZaid Al-KadhimiMitchell SabloffJohnnie J. OrozcoJames ForanPartow KebriaeiKatarzyna JamiesonMargarida Magalhaes-SilvermanKoen van BesienMichael W SchusterArjun Datt LawMoshe Yair LevyHillard M. LazarusSergio A GiraltMark S. BergerJennifer SprossAvinash DesaiVijay ReddyJohn M. Pagel
- Resource Type
- Abstract
- Publication Details
- Transplantation and cellular therapy, Vol.28(3), pp.S35-S36
- DOI
- 10.1016/S2666-6367(22)00201-9
- ISSN
- 2666-6367
- eISSN
- 2666-6367
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 03/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362305702771
Abstract
40 - High Rates of Transplantation in the Phase III Sierra Trial Utilizing Anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) Conditioning with Successful Engraftment and Tolerability in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) Patients after Lack of Response to Conventional Care and Targeted Therapies
Transplantation and cellular therapy, Vol.28(3), pp.S35-S36
03/2022
DOI: 10.1016/S2666-6367(22)00201-9
Details
Metrics
42 Record Views